Antibodies
|
Duke University
|
DC with GITRL/anti-CTLA-4 mAb mRNA (i.n.)
|
Metastatic melanoma
|
NCT01216436 (I)
|
Melanoma TAA mRNA transfected DCs
|
2010
|
Terminated (lack of personnel)
|
Immunomodulators
|
Cytokines
|
Medimmune LLC, Moderna TX Inc.
|
LNP with IL-12 mRNA (i.t.)
|
Solid tumors
|
NCT03946800 (I)
|
Durvalumab
|
2019
|
Recruiting
|
Moderna TX Inc., AstraZeneca
|
LNP with OX40L, IL-23 and IL-36γ mRNA (i.t.)
|
Relapsed/refractory solid tumor malignancies or lymphoma, TNBC, HNSCC, Non-Hodgkin lymphoma, urothelial cancer
|
NCT03739931 (I)
|
Durvalumab
|
2018
|
Recruiting [182]
|
Sanofi, BioNTech SE
|
scIL-12, IL-15sushi, IFNα and GM-CSF mRNA (i.t.)
|
Metastatic neoplasms
|
NCT03871348 (II, non-randomized)
|
Cemiplimab
|
2019
|
Recruiting
|
Stimulatory ligands and receptors
|
eTheRNA Immunotherapies Nv.
|
TriMix (CD70, CD40L, caTLR4) mRNA and TAA mRNA (i.n.)
|
Melanoma
|
NCT03394937 (I)
|
None
|
2018
|
Recruiting
|
Moderna TX Inc.
|
LNP-OX40L mRNA (i.t.)
|
Relapsed/refractory solid tumor malignancies or lymphoma, ovarian cancer
|
NCT03323398 (I/II, non-randomized)
|
Durvalumab
|
2017
|
Recruiting
|
Universitair Ziekenhuis Brussel, eTheRNA Immunotherapies Nv.
|
TriMix (CD70, CD40L, caTLR4) mRNA (i.t.)
|
Early resectable breast cancer
|
NCT03788083 (I)
|
None
|
2018
|
Recruiting
|